Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRE Stones
2022-502890-40-00Phase 3Authorised
- Sponsor
- CHRU Tours
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of furosemide in nephrolithiasis (2 arms), sponsored by CHRU Tours. Primary endpoint: Stone-free rate at 3 months. Planned start Sep 2023; status: authorised.
02
Drugs
furosemide
03
Conditions
nephrolithiasis
Beyond the preview
Go deeper on 2022-502890-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502890-40-00.